Contact the Editorial Desk

Editorial correspondence

Correspondence on the research record is welcome: a citation quoted inaccurately, a newly published study on epitalon or MOTS-c, or a regulatory update that shifts an approval or scheduling status. A correction that improves the accuracy or currency of the log is the most useful message that lands here, and each one is read and weighed directly.

The most actionable notes specify the page in question, the exact passage being corrected or challenged, and the supporting reference — a DOI or PubMed identifier wherever possible. That format lets a proposed change be checked against its source before it is acted on.

Editorial mailbox: editors@peptidebattery.com

What this desk cannot do

So that no message goes unanswered for the wrong reason, a few things sit outside this log's scope. Peptide Battery reads the literature; it is not a clinical service or a product vendor, so it cannot:

• Advise on, recommend, or comment on human use of epitalon, MOTS-c, or any other peptide.
• Suggest a dose, cycling schedule, or route of administration for any individual.
• Judge whether a cell-culture, animal-model, or observational finding applies to a specific person's situation.
• Sell, source, recommend, or help locate either compound from any supplier.
• Advise athletes under anti-doping rules, given that MOTS-c intersects with WADA/USADA monitoring.

Epitalon and MOTS-c are both unapproved research chemicals; a reader seeking medical guidance should consult a licensed clinician in their jurisdiction. Replies to editorial correspondence are not guaranteed and may be delayed; the mailbox is watched intermittently.